Results 41 to 50 of about 21,815 (182)

Waterfall plots of PSA response after enzalutamide according to initial dose of enzalutamide in 124 CRPC patients.

open access: yes, 2021
Waterfall plots of PSA response after enzalutamide according to initial dose of enzalutamide in 124 CRPC patients.
Jun Miki (11512692)   +10 more
core   +1 more source

Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. [PDF]

open access: yes, 2020
The second-generation antiandrogen, enzalutamide, is approved for castrate-resistant prostate cancer (CRPC) and targets androgen receptor (AR) activity in CRPC.
Hoang, David   +13 more
core   +1 more source

Identifying and Targeting Pathways Involved in Enzalutamide-Resistant Prostate Cancer

open access: yes, 2020
Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is an FDA-approved drug for treatment of patients with late-stage prostate cancer and is currently under ...
Farah, Elia
core   +1 more source

HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis

open access: yesTherapeutic Advances in Medical Oncology
Background: Talazoparib plus enzalutamide showed significant improvement of progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in homologous recombination repair (HRR) genes.
Mingjun Rui   +3 more
doaj   +1 more source

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis

open access: yesFrontiers in Endocrinology, 2023
IntroductionSecond-generation androgen receptor inhibitors (SGARIs), namely enzalutamide, apalutamide, and darolutamide, are good for improving survival outcomes in prostate cancer patients, but some researchers have shown that using SGARIs increases ...
Xiangyu Chen   +8 more
doaj   +1 more source

DLST Succinylation‐Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma

open access: yesAdvanced Science, EarlyView.
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li   +9 more
wiley   +1 more source

Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
The schematic diagram depicts a compartmentalized anti‐ferroptotic defense mechanism mediated by GSTA4. GSTA4 is upregulated and localizes to the cytoplasm in ENZR cells, where it detoxifies 4‐HNE via a non‐canonical GSH‐dependent pathway. Under oxidative stress, GSTA4 translocates to mitochondria, interacts with PGAM5, and blocks Drp1 Ser637 ...
Yong Luo   +17 more
wiley   +1 more source

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis

open access: yesJournal for ImmunoTherapy of Cancer, 2023
Background Enzalutamide, a next-generation antiandrogen agent, is approved for the treatment of metastatic castration-resistant prostate cancer (CRPC).
Jeffrey Schlom   +7 more
doaj   +1 more source

Antioxidant Programs Are Essential for Enzalutamide-Resistant Prostate Cancer

open access: yes, 2023
Therapy resistance to second generation androgen receptor (AR) antagonists, such as enzalutamide, is common in patients with advanced prostate cancer (PCa).
Blatt, Eliot Benjamin
core   +1 more source

An update on enzalutamide in the treatment of prostate cancer

open access: yesTherapeutic Advances in Urology, 2015
Enzalutamide is an oral androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway. In the randomized phase III AFFIRM study, significant improvements in survival versus placebo were observed when enzalutamide was ...
Axel S. Merseburger   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy